Pliant Therapeutics, Inc.
PLRX
$1.48
$0.010.68%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -100.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -100.00% |
| SG&A Expenses | 4.86% | -7.08% | 3.07% | 7.72% | -2.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.36% | 30.05% | 27.46% | 20.64% | 19.49% |
| Operating Income | -13.36% | -30.05% | -28.13% | -24.46% | -25.77% |
| Income Before Tax | -20.98% | -39.23% | -35.59% | -25.05% | -17.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.98% | -39.23% | -35.59% | -25.05% | -17.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.98% | -39.23% | -35.59% | -25.05% | -17.25% |
| EBIT | -13.36% | -30.05% | -28.13% | -24.46% | -25.77% |
| EBITDA | -13.50% | -30.16% | -28.10% | -24.58% | -26.06% |
| EPS Basic | -19.09% | -36.83% | -32.88% | -16.48% | 4.52% |
| Normalized Basic EPS | -19.10% | -36.86% | -32.87% | -16.48% | 3.79% |
| EPS Diluted | -19.09% | -36.83% | -32.88% | -16.48% | 4.52% |
| Normalized Diluted EPS | -19.10% | -36.86% | -32.87% | -16.48% | 3.79% |
| Average Basic Shares Outstanding | 1.59% | 1.75% | 2.04% | 7.36% | 22.80% |
| Average Diluted Shares Outstanding | 1.59% | 1.75% | 2.04% | 7.36% | 22.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |